台股 » 個股 » 神隆 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

神隆

(1789)
可現股當沖
  • 股價
    22.50
  • 漲跌
    ▲0.15
  • 漲幅
    +0.67%
  • 成交量
    377
  • 產業
    上市 生技醫療類股
  • 299人加入追蹤

    立即追蹤

  • 本地時間:14:30

     
神隆 (1789)籌碼相關-中國信託 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

中國信託 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2025/01/15222.1000.0022.1023940.51%
2025/01/0900.005.822.5722.60-5.8371-1.57%
2025/01/0600.00422.2022.20-4362-1.10%
2025/01/0200.00121.8521.85-1366-0.27%
2024/12/271522.751422.6722.5513650.27%
2024/12/26122.5500.0022.5513660.27%
2024/12/2000.00321.7021.60-3373-0.80%
2024/12/19322.0000.0021.8533600.83%
2024/11/2000.00523.4023.60-5374-1.33%
2024/11/19523.2100.0023.2553711.35%
2024/10/2500.00224.2524.25-2394-0.51%
2024/09/26125.4000.0025.2515960.17%
2024/09/04224.3000.0024.2528050.25%
2024/08/23225.2500.0025.3028790.23%
2024/08/05224.200.124.0023.951.91,1080.17%
2024/07/2900.00126.0025.85-11,117-0.09%
2024/07/2600.00226.1026.05-21,131-0.18%
2024/07/2200.001.226.4626.50-1.21,195-0.10%
2024/07/1900.005026.3526.35-501,198-4.17%
2024/07/18126.90127.0026.8501,1880.00%
2024/07/11227.80127.6027.4511,2150.08%
2024/07/1000.000.228.4128.05-0.21,208-0.01%
2024/07/050.228.7000.0028.900.21,2390.01%
2024/07/03429.00628.9228.90-21,301-0.15%
2024/07/02229.2000.0028.8521,3320.15%
2024/07/0126.129.73129.4529.4525.11,3431.87%
2024/06/280.129.201429.1829.00-13.91,329-1.05%
2024/06/2700.00129.2028.95-11,324-0.08%
2024/06/2400.00128.3028.25-11,489-0.07%
2024/06/20328.451028.3328.40-71,491-0.47%
2024/06/1700.001329.1329.10-131,547-0.84%
2024/06/1400.001028.2528.80-101,537-0.65%
2024/06/13228.5000.0028.3521,5420.13%
2024/06/12328.8000.0028.8031,5430.19%
2024/06/1100.00229.2029.20-21,538-0.13%
2024/06/06728.5700.0028.5071,5040.47%
2024/06/053828.891028.6528.90281,5121.85%
2024/06/0400.00128.4528.90-11,512-0.07%
2024/06/0300.00228.0028.05-21,502-0.13%
2024/05/3100.00227.8027.85-21,497-0.13%
2024/05/30328.0500.0027.8031,5030.20%
2024/05/2900.00228.5028.15-21,498-0.13%
2024/05/28328.40128.5028.5021,4910.13%
2024/05/2700.00228.0028.10-21,485-0.13%
2024/05/2300.00128.5528.35-11,478-0.07%
2024/05/221228.88829.0028.6541,4760.27%
2024/05/212429.941529.8129.3591,4530.62%
2024/05/208.129.043.129.1129.3551,3870.36%
2024/05/17228.60228.4528.6001,3410.00%
2024/05/16527.9000.0028.1051,3180.38%
2024/05/1400.00127.5527.50-11,309-0.08%
2024/05/13127.8000.0027.6011,3060.08%
2024/05/10127.6500.0027.5511,3060.08%
2024/05/0900.000.227.5527.60-0.21,299-0.01%
2024/05/07528.42128.3028.2041,2880.31%
2024/05/06128.301028.3028.30-91,274-0.71%
2024/05/0300.00228.5028.40-21,267-0.16%
2024/05/02128.85328.7728.65-21,257-0.16%
2024/04/306.128.88528.7628.701.11,2510.08%
2024/04/29828.98428.9829.1041,2280.33%
2024/04/266.128.13328.4328.153.11,1760.26%
2024/04/254.128.07328.1028.201.11,1580.09%
2024/04/24428.000.227.7527.953.81,1580.33%
2024/04/230.127.45127.9028.00-0.91,161-0.08%
2024/04/22127.0000.0027.4511,1540.09%
2024/04/1900.00327.0026.75-31,147-0.26%
2024/04/1700.00227.4027.75-21,126-0.18%
2024/04/1600.002.126.9526.95-2.11,118-0.19%
2024/04/15127.40527.4427.45-41,111-0.36%
2024/04/12227.6000.0027.4521,0970.18%
2024/04/117.228.27128.7528.056.21,0690.58%
2024/04/10628.68928.7928.70-31,040-0.29%
2024/04/09127.8500.0027.8019850.10%
2024/04/08428.312.228.3928.301.89620.19%
2024/04/0300.00127.3027.75-1919-0.11%
2024/04/02427.711227.6527.60-8894-0.89%
2024/04/0100.00127.4527.45-1885-0.11%
2024/03/29327.68128.4027.6528760.23%
2024/03/2819.227.771127.7927.658.28211.00%
2024/03/27226.55126.6026.6516990.14%
2024/03/2600.000.226.5526.05-0.2689-0.02%
2024/03/22126.30326.3526.50-2679-0.29%
2024/03/21226.53126.3526.4016740.15%
2024/03/20426.651.526.5026.702.56610.38%
2024/03/1900.00125.7025.75-1606-0.16%
2024/03/18126.1000.0025.4016070.16%
2024/03/15125.8500.0026.1015890.17%
2024/03/13125.5500.0025.6515740.17%
2024/03/11125.00125.2025.3505710.00%
2024/03/08125.00125.1024.5005600.00%
2024/03/0700.00225.1525.10-2566-0.35%
2024/02/2300.000.125.3025.15-0.1608-0.02%
2024/02/1900.00325.5525.55-3614-0.49%
2024/02/1600.000.525.5025.55-0.5614-0.08%
漢達私募引進神隆成第二大股東 攜手拓展改良型新藥Anue鉅亨-2024/12/20
逸達前列腺癌新藥獲美藥證 神隆同步受惠Anue鉅亨-2021/05/27
神隆 相關文章